Quantitative analysis for Lineage Cell Therapeutics, Inc. (LCTX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (14.0) (grade F). 28 signals analyzed (25 differentiated alt-data).
LCTX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $1.58 | $1.46 | $1.46 |
| 2026-05-11 | $1.43 | $1.31 | $1.31 |
| 2026-05-21 | $1.34 | $1.26 | $1.32 |
| 2026-06-03 | $1.23 | $1.19 | $1.20 |
| 2026-06-15 | $1.32 | $1.23 | $1.23 |
| 2026-06-26 | $1.30 | $1.20 | $1.28 |
| 2026-07-09 | $1.35 | $1.27 | $1.29 |
| 2026-07-21 | $1.14 | $1.10 | $1.14 |
| 2026-07-31 | $1.12 | $1.07 | $1.08 |
| 2026-08-12 | $1.13 | $1.09 | $1.10 |
| 2026-08-24 | $1.11 | $1.06 | $1.09 |
| 2026-09-03 | $1.12 | $1.09 | $1.10 |
How Lineage Cell Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AUNA | Auna S.A. | $324M | — |
| NMRA | Neumora Therapeutics, Inc. Common Stock | $319M | — |
| PALI | Palisade Bio, Inc. | $326M | 43.0 |
| OVID | Ovid Therapeutics Inc. | $315M | — |
View all Health Care stocks by valuation and signals →
Lineage Cell Therapeutics, Inc. (LCTX) scores Strong Sell (14.0), and the composite conceals a 87-point disagreement between its dimensions. It is strongest on competitive moat at 91 and analyst consensus at 74, and weakest on technicals at 4. A stock can carry competitive moat that high while technicals sits at 4; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 91 |
| analyst consensus | 74 |
| technicals | 4 |
StoQuant analyzes 28 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Lineage Cell Therapeutics, Inc. (LCTX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/LCTX"><img src="https://stoquant.com/badge/LCTX.svg" alt="Lineage Cell Therapeutics, Inc. (LCTX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.